Americans are seeing dramatic Medicare drug price cuts, but critics say the Trump deal would have saved seniors and taxpayers even more—exposing ongoing frustrations with heavy-handed government programs.
Story Snapshot
Medicare announced significant price reductions for 15 high-cost prescription drugs, including Ozempic and Wegovy, set to begin in 2027.
The reductions stem from a Biden-era law, but experts argue Trump’s private-sector deal would have delivered bigger savings for seniors and taxpayers.
Conservatives warn that government-negotiated pricing programs risk limiting choice and pushing drugmakers out of Medicare, threatening access.
Trump’s administration remains focused on market-based reforms, voluntary deals, and regulatory relief to lower costs without government overreach.
Medicare Drug Price Cuts Roll Out Under Biden-Era Law
On November 25, 2025, the Centers for Medicare and Medicaid Services announced long-awaited price cuts on 15 expensive prescription drugs, including the widely used diabetes and weight-loss medications Ozempic and Wegovy. These reductions, set to take effect in 2027, are the result of the Medicare drug price negotiation program established under the Inflation Reduction Act, a sweeping law passed during Joe Biden’s presidency. While the measure promises savings for Medicare and its enrollees, the program’s approach diverges sharply from the market-driven philosophy favored by conservatives and the Trump administration.
Medicare announces price cuts for 15 prescription drugs, including Ozempic
“The lower prices stem from the Medicare negotiation program created under the Biden administration's Inflation Reduction Act,” @BerkeleyJr reports.https://t.co/QzSsf7iPtS
The Trump administration has favored a dramatically different path to lowering drug prices—one that relies on executive action and voluntary agreements with manufacturers, not heavy-handed government mandates. President Trump recently announced a direct deal with Novo Nordisk, the maker of Ozempic and Wegovy, securing a $250 monthly price, which undercuts the $274 negotiated by Medicare’s program. Health policy experts, like Stacie Dusetzina of Vanderbilt University, have observed that Medicare’s negotiated price is actually higher than the Trump-negotiated deal, meaning taxpayers and beneficiaries are missing out on even greater savings. This underscores the effectiveness of negotiating directly with industry partners rather than relying on government bureaucracy.
Conservative Concerns: Government Overreach and Access Risks
Many conservatives remain wary of federal programs that expand government power over the private sector. Under the current Medicare negotiation program, drugmakers are technically free to decline participation, but doing so would force them to withdraw their products from the Medicare market entirely—effectively limiting seniors’ access to critical medicines. While drugmakers have challenged the program in court, they have yet to prevail. This structure raises red flags about government overreach and the potential for bureaucratic decisions to erode patient choice and innovation, a recurring concern for those who value free-market solutions and constitutional limits on federal authority.
The negotiated prices represent what Medicare will pay drugmakers, not what patients pay out of pocket. The government expects to save $12 billion, and Medicare enrollees could see $685 million in reduced out-of-pocket costs in 2027. However, critics argue that these savings come at the price of reduced competition, and the possibility that drugmakers could exit the Medicare market entirely if profit margins are squeezed too tightly. The 15 drugs affected accounted for $42.5 billion in Medicare Part D spending in 2024—a testament to the stakes of these negotiations.
Americans Still Struggle With High Drug Costs
Despite headline-grabbing cuts, many Americans continue to struggle with unaffordable prescription drug prices. Survey data from the health policy group KFF shows that about 1 in 5 adults have skipped filling a prescription due to cost, and 1 in 7 have rationed their medication in the past year. These statistics reflect the urgent need for real solutions that lower costs without sacrificing choice or quality. Conservatives point to Trump’s record of achieving results through regulatory relief, voluntary deals, and putting American patients first—contrasting sharply with the Biden-era approach of expanding government control and regulation.
Trump Administration’s Broader Health Care Strategy
President Trump’s administration has remained generally quiet about the Medicare negotiation program, instead focusing on a broader strategy of health care deregulation and market-driven reforms. Health and Human Services Secretary Robert F. Kennedy Jr. emphasized a commitment to “stop at nothing to lower health care costs for the American people,” using every available tool to ensure affordable care for seniors. Republicans continue to argue that a return to common-sense, constitutional principles—limited government, free enterprise, and patient empowerment—offers the best path forward for American health care.
